drugset
drugset / Trial / NCT03621696

Surgery Followed by Risk-Directed Post-Operative Adjuvant Therapy for HPV-Related Oropharynx Squamous Cell Carcinoma: "The Minimalist Trial (MINT)"

NCT03621696 ↗

Phase 2 Completed 63 enrolled Washington University School of Medicine
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The overarching goal of the MINT trial is to reduce treatment-related toxicity while maintaining efficacy. Patients with HPV-related oropharyngeal squamous cell carcinoma (OPSCC) will undergo resection of the primary tumor site and involved/at risk regional neck nodes.

Timeline

Start
2018-10-23
Primary completion
2021-03-10
Completion
2026-03-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified 100 mg/m2 Intravenous

Indications

oropharynx squamous cell carcinoma